Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

GNC’s Chinese Backer to Consider Buyout of Vitamin Retailer

By Bloomberg / Oct 23, 2019 03:10 AM / Business & Tech

Photo: Bloomberg

Photo: Bloomberg

GNC Holdings Inc.’s Chinese investor, Harbin Pharmaceutical Group Co., is considering a potential bid to take the U.S. vitamin and supplement retailer private, people with knowledge of the matter said.

The Chinese company has been speaking with potential advisers about an offer for GNC, the people said, asking not to be identified because the information is private. GNC has lost more than half its value over the past year, giving it a market capitalization of $176 million at Monday’s close. The company had nearly $900 million of debt at the end of June, according to a recent investor presentation.

Shares of GNC jumped 16% in pre-market trading Tuesday.

Harbin Pharmaceutical agreed last year to buy $300 million of GNC convertible preferred shares, which would make it the U.S. company’s biggest shareholder if they were all exercised. The two companies also recently started a Chinese e-commerce joint venture.

Any transaction would mark a rare U.S. acquisition by a Chinese company as ongoing trade tensions slow cross-border deal making. GNC has been in talks with creditors about ways to rework its debt load, Bloomberg News reported last month.

Regulatory Risks

Harbin Pharmaceutical, known for its Hayao medicine brand, is in the early stages of weighing an offer and hasn’t made a final decision on whether to proceed, the people said. It is studying risks including the potential for regulatory scrutiny and the possibility that GNC’s business will further deteriorate, as well as the debt load it would need to take on, according to the people.

GNC has been considering a range of refinancing options and aims to complete the process by year-end, according to one person. Representatives for Harbin Pharmaceutical didn’t immediately respond to requests for comment, while a representative for GNC declined to comment.

Shares of Harbin Pharmaceutical have climbed 7% in the past 12 months, giving it a market value of about 9.6 billion yuan ($1.3 billion).

GNC, founded in the 1930s, sells health and nutrition products in more than 4,800 stores across the U.S. as well as through franchise operations in 46 international markets, according to its website. The retailer plans to close as many as 900 stores by end of next year in the U.S., Chief Executive Officer Ken Martindale said on a July 22 investors call.

The American company held discussions with several Chinese suitors about a sale of the entire business in 2016, though the talks stalled after they failed to agree on a deal structure, people familiar with the matter said at the time.


Share this article
Open WeChat and scan the QR code